AcquisitionsMay 15, 2026, 07:47 AM
Sensei Acquires Faeth, Raises $200M in Private Placement; Q1 Net Loss $170.2M
AI Summary
Sensei Biotherapeutics acquired Faeth Therapeutics on February 17, 2026, for $145.8 million, concurrently raising $200 million in gross proceeds through a private placement of Series B Preferred Stock. This strategic move significantly bolstered the company's cash position to $202.8 million. However, the acquisition led to a substantial increase in net loss to $170.2 million for Q1 2026, primarily due to a $132.9 million expense for acquired in-process research and development. Despite the improved liquidity, the company disclosed substantial doubt about its ability to continue as a going concern.
Key Highlights
- Acquired Faeth Therapeutics on February 17, 2026, for $145.8 million.
- Raised $200 million in gross proceeds from a private placement of Series B Preferred Stock.
- Reported a net loss of $170.2 million for the three months ended March 31, 2026.
- Expensed $132.9 million for acquired in-process research and development.
- Cash, cash equivalents, and marketable securities totaled $202.8 million as of March 31, 2026.
- Research and development expenses increased to $17.96 million, up 382% year-over-year.
- General and administrative expenses rose to $19.71 million, up 455% year-over-year.
- Company identified substantial doubt about its ability to continue as a going concern.
Price Impact
More from SNSE